Cost-Effectiveness of Pharmacotherapy for the Treatment of Obesity in Adolescents
JAMA Network Open · 2023
DOI: 10.1001/jamanetworkopen.2023.29178 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, 2023. Verfasst von Francesca Lim und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Columbia University Irving Medical Center, New York, New York. Hauptthemen laut MEDLINE: Pediatric Obesity. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
Importance Antiobesity pharmacotherapy is recommended for adolescents ages 12 years and older with obesity. Several medications have been approved by the US Food and Drug Administration for adolescent use, but the most cost-effective medication remains unclear.
Objective
To estimate the cost-effectiveness of lifestyle counseling alone and as adjunct to liraglutide, mid-dose phentermine and topiramate (7.5 mg phentermine and 46 mg topiramate), top-dose phentermine and topiramate (15 mg phentermine and 92 mg topiramate), or semaglutide among adolescent patients with obesity. Design, Setting, and Participants This economic evaluation used a microsimulation model to project health and cost outcomes of lifestyle counseling alone and adjunct to liraglutide, mid-dose phentermine and topiramate, top-dose phentermine and topiramate, or semaglutide over 13 months, 2 years, and 5 years among a hypothetical cohort of 100 000 adolescents with obesity, defined as an initial body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) of 37. Model inputs were derived from clinical trials, published literature, and national sources. Data were analyzed from April 2022 to July 2023. Exposures Lifestyle counseling alone and as adjunct to liraglutide, mid-dose phentermine and topiramate, top-dose phentermine and topiramate, or semaglutide. Main Outcomes and Measures The main outcome was quality-adjusted life years (QALYs), costs (2022 US dollars), and incremental cost-effectiveness ratios (ICERs), with future costs and QALYs discounted 3.0% annually. A strategy was considered cost-effective if the ICER was less than $100 000 per QALY gained. The preferred strategy was determined as the strategy with the greatest increase in QALYs while being cost-effective. One-way and probabilistic sensitivity analyses were used to assess parameter uncertainty.
Results
The model simulated 100 000 adolescents at age 15 with an initial BMI of 37, of whom 58 000 (58%) were female. At 13 months and 2 years, lifestyle counseling was estimated to be the preferred strategy. At 5 years, top-dose phentermine and topiramate was projected to be the preferred strategy with an ICER of $56 876 per QALY gained vs lifestyle counseling. Semaglutide was projected to yield the most QALYs, but with an unfavorable ICER of $1.1 million per QALY gained compared with top-dose phentermine and topiramate. Model results were most sensitive to utility of weight reduction and weight loss of lifestyle counseling and top-dose phentermine and topiramate. Conclusions and Relevance In this economic evaluation of pharmacotherapy for adolescents with obesity, top-dose phentermine and topiramate as adjunct to lifestyle counseling was estimated to be cost-effective after 5 years. Long-term clinical trials in adolescents are needed to fully evaluate the outcomes of pharmacotherapy, especially into adulthood.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Columbia University Irving Medical Center, New York, New York.
- Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York.
- Department of Pediatrics, Columbia University Irving Medical Center, New York, New York.
- Department of Pediatrics and Center for Pediatric Obesity Medicine, University of Minnesota Medical School, Minneapolis.
Förderung
- NIDDK NIH HHS
- NHLBI NIH HHS
Zitieren
APA
Lim, F., Bellows, B. K., Tan, S. X., Aziz, Z., Woo Baidal, J. A., Kelly, A. S., & Hur, C. (2023). Cost-Effectiveness of Pharmacotherapy for the Treatment of Obesity in Adolescents. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2023.29178
Vancouver
Lim F, Bellows BK, Tan SX, Aziz Z, Woo Baidal JA, Kelly AS, et al. Cost-Effectiveness of Pharmacotherapy for the Treatment of Obesity in Adolescents. JAMA Network Open. 2023. doi:10.1001/jamanetworkopen.2023.29178
BibTeX
@article{Lim2023,
author = {Lim, Francesca and Bellows, Brandon K and Tan, Sarah Xinhui and Aziz, Zainab and Woo Baidal, Jennifer A and Kelly, Aaron S and Hur, Chin},
title = {Cost-Effectiveness of Pharmacotherapy for the Treatment of Obesity in Adolescents},
journal = {JAMA Network Open},
year = {2023},
doi = {10.1001/jamanetworkopen.2023.29178}
}
EUVIMED